


AMENDMENTS TO THE CLAIMS

1. (Currently amended): A compound of Formula (I):



(I)

or a salt, or solvate, or physiologically functional derivative thereof wherein

A is the group defined by (Q⁴)_p-(Q³)_n-(Q²)_m-(Q¹)-, wherein

Q¹ is heterocyclyl or heterocyclylene,

Q² is OC(O), C(O), N(H)C(O), C(O)N(H)C(O), S(O)₂N(H)C(O), S(O)₂, or N(H)S(O)₂ and m is 0 or 1,

Q³ is C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, aralkyl, aralkylene, aryl, arylene, heteroaryl, heteroarylene, heterocyclyl, or heterocyclylene, and n is 0 or 1, and

Q⁴ is C₁-C₆ alkyl, C₁-C₆ haloalkyl, aryl, aryloxy, heteroaryl, halo, or cyano, and p is 0, 1, or 2;

D is O or S;

R is hydrogen or -N(R¹)-R²-R³;

R¹ is hydrogen or C₁-C₆ alkyl;


R² is C(O), C(O)O, C(O)N(H), SO₂, or SO₂N(H);

R³ is hydrogen or C₁-C₆ alkyl;

Z is the group defined by $-(X)_{\text{t}_m}-(X^1)$, wherein

X is $C(R')(R'')$, wherein R' is hydrogen or C_1-C_6 alkyl, R'' is hydrogen or C_1-C_6 alkyl, and t_m is 0, 1, or 2; and
X¹ is aryl, heteroaryl, or heterocyclyl.

2. (Currently amended) A compound of Formula (II):



II

or a salt, solvate, or physiologically functional derivative thereof wherein

A' is the group defined by $(Q^4)_p-(Q^3)_n-(Q^2)_m-$, wherein

Q^2 is $OC(O)$, $C(O)$, $N(H)C(O)$, $C(O)N(H)C(O)$, $S(O)_2N(H)C(O)$, $S(O)_2$, or $N(H)S(O)_2$ and m is 0 or 1,

Q^3 is C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_3-C_7 cycloalkyl, aralkyl, aralkylene, aryl, arylene, heteroaryl, heteroarylene, heterocyclyl, or heterocyclene, and n is 0 or 1, and

Q^4 is C_1-C_6 alkyl, C_1-C_6 haloalkyl, aryl, aryloxy, heteroaryl, halo, or cyano, and p is 0, 1, or 2;

R^a is hydrogen or oxo;

R^b is hydrogen or C_1-C_6 alkyl;

R^c is hydrogen or C_1-C_6 alkyl;

R is hydrogen or $-N(R^1)-R^2-R^3$;

R¹ is hydrogen or C_1-C_6 alkyl;

R² is $C(O)$, $C(O)O$, $C(O)N(H)$, SO_2 , or $SO_2N(H)$;

R^3 is hydrogen or C_1-C_6 alkyl;

Z is the group defined by $-(X)_{\underline{t}m}-(X^1)$, wherein

X is $C(R')(R'')$, wherein R' is hydrogen or C_1-C_6 alkyl, R'' is hydrogen or C_1-C_6 alkyl, and $\underline{t}m$ is 0, 1, or 2; and

X^1 is aryl, heteroaryl, or heterocyclyl.

3. (Original) A compound as claimed in claim 1, wherein m is 0, n is 0, and p is 0 and A is $(Q^1)-$.

4. (Original) A compound as claimed in claim 1, wherein n is 0, p is 0 and A is $(Q^2)_m-(Q^1)-$.


5. (Original) A compound as claimed in claim 1, wherein p is 0 and A is $(Q^3)_n-(Q^2)_m-(Q^1)-$.

6. (Original) A compound as claimed in claim 1, wherein m is 0, n is 1, p is 0, 1, or 2, and A is $(Q^4)_p-(Q^3)-(Q^1)-$.

7. (Original) A compound as claimed in claim 1, wherein Q^1 is heterocyclyl.


8. (Original) A compound as claimed in claim 1, wherein Q^1 is heterocyclene.

9. (Original) A compound as claimed in claim 1, wherein Q^1 is selected from the group



wherein R^b is hydrogen or C_1-C_6 alkyl and R^c is hydrogen or C_1-C_6 alkyl.


10. (Original) A compound as claimed in claim 1, wherein Q¹ is selected from the group



, wherein R^b is hydrogen or C₁-C₆ alkyl and


R^c is hydrogen or C₁-C₆ alkyl.

11. (Original) A compound as claimed in claim 1, wherein Q¹ is



, wherein R^b is hydrogen or C₁-C₆ alkyl and R^c is hydrogen or C₁-C₆ alkyl.


12. (Original) A compound as claimed in claim 1, wherein Q¹ is selected from the group



, wherein R^b is hydrogen or C₁-C₆ alkyl and

R^c is hydrogen or C₁-C₆ alkyl.

13. (Original) A compound as claimed in claim 1, wherein Q¹ is selected from the group



, wherein R^b is hydrogen or C₁-C₆ alkyl and R^c is hydrogen or C₁-C₆ alkyl.

14. (Previously presented) A compound as claimed in claim 1 wherein m is 1 and Q² is OC(O), C(O), N(H)C(O), S(O)₂, or N(H)S(O)₂.

15. (Previously presented) A compound as claimed in claim 1 wherein m is 1 and Q² is OC(O) or C(O).

16. (Previously presented) A compound as claimed in claim 1 wherein m is 1 and Q² is C(O).


17. (Previously presented) A compound as claimed in claim 1 wherein m is 1 and Q² is N(H)C(O).

18. (Previously presented) A compound as claimed in claim 1, wherein m is 1 and Q² is S(O)₂.


19. (Previously presented) A compound as claimed in claim 1 wherein n is 1 and Q³ is aryl or arylene, heteroaryl or heterarylene, heterocycl or heterocyclene, or aralkyl or aralkylene.

20. (Previously presented) A compound as claimed in claim 1 wherein, Q³ is aryl or arylene.

21. (Previously presented) A compound as claimed in claim 1 wherein Q³ is selected from the group




22. (Previously presented) A compound as claimed in claim 1 wherein Q³ is




23. (Previously presented) A compound as claimed in claim 1 wherein Q³ is aralkyl or aralkylene.


24. (Previously presented) A compound as claimed in claim 1 wherein Q³ is selected from the group



25. (Previously presented) A compound as claimed in claim 1 wherein Q³ is selected




26. (Original) A compound as claimed in claim 2, wherein Q³ is selected from the




27. (Previously presented) A compound as claimed in claim 1 wherein Q^3 is heteroaryl or heteroarylene.

28. (Previously presented) A compound as claimed in claim 1 wherein Q^3 is selected from the group



29. (Previously presented) A compound as claimed in claim 1 wherein Q^3 is heterocyclyl or heterocyclylene.

30. (Previously presented) A compound as claimed in claim 1 wherein Q³ is selected from the group



31. (Previously presented) A compound as claimed in claim 1 wherein Q⁴ is methyl, tert-butyl, -CF₃, phenyl, phenoxy, isoxazolyl, thiadiazolyl, thienyl, pyrazinyl, fluoro, chloro, cyano, and p is 1 or 2.

32. (Previously presented) A compound as claimed in claim 1 wherein Q⁴ is methyl, tert-butyl, -CF₃, phenyl, phenoxy, and fluoro and p is 1 or 2.

33. (Previously presented) A compound as claimed in claim 1 wherein Q⁴ is methyl, and p is 1.

34. (Previously presented) A compound as claimed in claim 1 wherein D is O.

35. (Previously presented) A compound as claimed in claim 1 wherein R is hydrogen.


36. (Previously presented) A compound as recited in claim 1 wherein m is 0 and Z is -(X¹).

37. (Previously presented) A compound as claimed in claim 1 wherein X is CHR'', R'' is hydrogen and m is 0, 1, or 2.

38. (Previously presented) A compound as claimed in claim 1 wherein X is CHR", R" is -CH₃ and m is 1.


39. (Previously presented) A compound as claimed in claim 1 wherein X¹ is aryl.

40. (Previously presented) A compound as claimed in claim 1 wherein X¹ is



41. (Previously presented) A compound as claimed in claim 1 wherein X¹ is heteroaryl or heterocyclyl.

42. (Previously presented) A compound as claimed in claim 1 wherein X¹ is



43. (Currently amended): A compound as claimed in claim 1, selected from the group consisting of:

(3S)-4,4-dimethyl-2-oxotetrahydro-3-furanyl (1S)-1-(oxo{[(1R)-1-phenylethyl] amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-2-oxotetrahydro-3-furanyl (1S)-5-{{(methylamino) carbonyl] amino}-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(4S)-4-ethyl-4-methyl-2-oxotetrahydro-3-furanyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

1-benzyl-4,4-dimethyl-2-oxo-3-pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl] amino}acetyl) pentylcarbamate;

benzyl 4,4-dimethyl-2-oxo-3-[([(1S)-1-(oxo{[(1R)-1-phenylethyl]amino} acetyl) pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;

3S)-4,4-dimethyl-2-oxopyrrolidinyl (1S)-1-(1-hydroxy-2-oxo-2-[(1R)-1-phenylethyl]amino}ethyl)pentylcarbamate;

(3R)-4,4-dimethyl-2-oxopyrrolidinyl (1S)-1-(1-hydroxy-2-oxo-2-[(1R)-1-phenylethyl] amino}ethyl)pentylcarbamate;

1,4,4-trimethyl-2-oxo-3-pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-benzyl-4,4-dimethylpyrrolidinyl 1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-benzoyl-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-acetyl-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-(phenylacetyl)pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-(5-isoxazolylcarbonyl)-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-[(4-methyl-1,2,3-thiadiazol-5-yl)carbonyl]pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-[(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)carbonyl]-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)carbonyl]pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-(1,3-benzodioxol-5-ylcarbonyl)-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-(1-benzothien-2-ylcarbonyl)-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-(2-naphthoyl)pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-[(5-methyl-3-isoxazolyl)carbonyl]pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-[(1,1'-biphenyl)-4-ylcarbonyl]-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-(1H-indol-5-ylcarbonyl)-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-(1H-1,2,3-benzotriazol-5-ylcarbonyl)-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-[(3-phenoxyphenyl)acetyl]pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-(4-phenylbutanoyl)pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-[(4-tert-butylphenyl)acetyl]-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-[(2-(4-pyridinyl)-1,3-thiazol-4-yl)carbonyl]pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-[(1-methyl-1H-indol-2-yl)carbonyl]pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-(3-quinolinylcarbonyl)pyrrolidinyl 1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-[(1,1'-biphenyl)-4-ylacetyl]-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-[(2-phenoxyphenyl)acetyl]pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-(1H-indol-2-ylcarbonyl)-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-(3-pyridinylacetyl)pyrrolidinyl 1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-(1H-1,2,4-triazol-3-ylcarbonyl)pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-[(3-methyl-5-isoxazolyl)acetyl]pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-(1H-indazol-3-ylcarbonyl)-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-{{2-(4-methyl-1,2,3-thiadiazol-5-yl)-1,3-thiazol-4-yl}carbonyl}pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-{{2-(2-pyrazinyl)-1,3-thiazol-4-yl}acetyl}pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-[(4-fluorophenyl)acetyl]-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

[1,1'-biphenyl]-4-ylmethyl (4S)-3,3-dimethyl-4-{{[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl}oxy]-1-pyrrolidinecarboxylate;

tetrahydro-2-furanylmethyl (4S)-3,3-dimethyl-4-{{[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl}oxy]-1-pyrrolidinecarboxylate;

3-thienylmethyl (4S)-3,3-dimethyl-4-{{[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl}oxy]-1-pyrrolidinecarboxylate;

(3S)-tetrahydro-3-furanyl (4S)-3,3-dimethyl-4-{{[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl}oxy]-1-pyrrolidinecarboxylate;

benzyl (4S)-3,3-dimethyl-4-{{[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl}oxy]-1-pyrrolidinecarboxylate;

2-phenylethyl (4S)-3,3-dimethyl-4-{{[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl}oxy]-1-pyrrolidinecarboxylate;

(1-phenyl-1H-1,2,3-triazol-4-yl)methyl (4S)-3,3-dimethyl-4-{{[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl}oxy]-1-pyrrolidinecarboxylate;

2-(2-oxo-1-pyrrolidinyl)ethyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
tetrahydro-2H-pyran-2-ylmethyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
tetrahydro-3-furanyl methyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
[3-methyl-5-(5-methyl-isoxazol-3-yl)-4-isoxazolyl]methyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
2-(4-methyl-1,3-thiazol-5-yl)ethyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
(5-methyl-3-isoxazolyl)methyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]methyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
(2-methyl[1,1'-biphenyl]-3-yl)methyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
[5-(2-thienyl)-1,2,4-oxadiazol-3-yl]methyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
(3R)-tetrahydro-3-furanyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
[1,1'-biphenyl]-4-yl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
4-phenoxyphenyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
3-phenoxyphenyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
2-naphthyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;
4-(1,2,3-thiadiazol-4-yl)phenyl (4S)-3,3-dimethyl-4-[(*[(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl)oxy]-1-pyrrolidinecarboxylate;***************

phenyl 3,3-dimethyl-4-[([(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl]amino}carbonyl]oxy]-1-pyrrolidinecarboxylate;

(3S)-1-(anilinocarbonyl)-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-[(benzylamino)carbonyl]-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;)

(3S)-4,4-dimethyl-1-[(2-phenylethyl)amino]carbonyl}pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-(3-pyridinylcarbonyl)pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-[(3,5-dimethyl-4-isoxazolyl)amino]carbonyl}-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-[(cyclohexylamino)carbonyl]-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-[(4-cyanoanilino)carbonyl]-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-[(4-(trifluoromethyl)anilino]carbonyl}pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-[(4-(trifluoromethyl)anilino]carbonyl}pyrrolidinyl (1S)-1-[oxo(1H-pyrazol-5-ylamino)acetyl]pentylcarbamate;

(3S)-1-[(5-fluoro-2-methylanilino)carbonyl]-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-(4-morpholinylcarbonyl)pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-(1-pyrrolidinylcarbonyl)pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-[(benzoylamino)carbonyl]-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-([(4-methylphenyl)sulfonyl]amino}carbonyl)pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-4,4-dimethyl-1-(phenylsulfonyl)pyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-(benzylsulfonyl)-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-(1,3-benzodioxol-5-ylsulfonyl)-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl] amino} acetyl) pentylcarbamate;

(3S)-1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4,4-dimethylpyrrolidinyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(3S)-1-(1,3-benzothiazol-2-yl)-4,4-dimethylpyrrolidinyl (1S)-1-[oxo(1H-pyrazol-5-ylamino)acetyl]pentylcarbamate;

(3S)-4,4-dimethyl-1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]pyrrolidinyl (1S)-1-[oxo(1H-pyrazol-5-ylamino)acetyl]pentylcarbamate; and

(3S)-4,4-dimethyltetrahydro-3-furanyl 1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

or a salt, or solvate, or physiologically functional derivative thereof.

44. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound as claimed in claim 1, or a salt, or solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

45. (Currently amended) A method of treating a disorder in a mammal, said disorder being characterized by an imbalance between bone resorption and formation which can ultimately lead to fracture, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in claim 1 or a salt, or solvate or a physiologically functional derivative thereof.

46. (Currently amended) A method of treating a disorder in a mammal, said disorder being characterized by bone loss, comprising: administering to said mammal a

therapeutically effective amount of a compound as claimed in claim 1 or a salt, or solvate ~~or a physiologically functional derivative~~ thereof.

47-48. (Cancelled):

49. (Currently Amended) A method of treating osteoporosis, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in claim 1, or a salt, or solvate ~~or physiologically functional derivative~~ thereof.

50. (Currently Amended) A method of treating osteoporosis, comprising: administering to said mammal therapeutically effective amounts of (i) a compound as claimed in claim 1, or a salt, or solvate ~~or physiologically functional derivative~~ thereof and (ii) at least one bone building agent.